Clinical Trials

Allogene is committed to the development of AlloCAR TTM therapies for cancer. Successful clinical trials are required to gain regulatory approval for new medications to advance patient care and may be required to support any approved products.

A list of existing Allogene clinical trials are below. For more information on Allogene clinical trials that may be recruiting, search “Allogene” at www.clinicaltrials.gov.

Program
ALLO-501
Phase
1
Sponsor
Allogene
Indication

The ALPHA Trial: Relapsed or refractory non-Hodgkin lymphoma (NHL)

Program
UCART19
Phase
1
Sponsor
Servier
Indication

The PALL Trial: Relapsed or refractory Acute lymphoblastic leukemia (ALL) in pediatric patients

Program
UCART19
Phase
1
Sponsor
Servier
Indication

The CALM Trial: Relapsed or refractory ALL in adults

Allogene’s Expanded Access Policy

Allogene does not currently have any active Expanded Access protocols but we do have Clinical Trials open. These can be found on ClinicalTrials.gov.

Treating physicians may request information about Expanded Access for an Allogene therapy by contacting our clinical trials team by phone or email at:

Allogene will evaluate these requests individually and may provide physician requested Expanded Access for an Allogene therapy for patients with no other available therapies and for patients who are not eligible to participate in a current Allogene clinical trial. Allogene will acknowledge receipt of the request via telephone call or email within 5 business days of receipt of the request.

Pursuant to the 21st Century Cures Act: the posting of policies by manufacturers and distributors shall not serve as a guarantee of access to any specific investigational therapy by any individual patient.